Adjuvant durvalumab after successful concomitant chemoradiotherapy of non-small cell lung cancer treatment
2021
Abstract
Lung cancer belongs on the top places among cancers regarding incidence and mortality. Most patients with lung cancer are coming to a doctor already with locally advanced or metastatic cancer stage III-IV.
Concomitant chemoradiotherapy is the standard treatment in patients with unresectable stage III. Despite the radical treatment attempt most of patients progress in less than 12 month.
Adjuvant durvalumab immunotherapy after successful concomitant chemoradiotherapy as a first brought benefit; durvalumab is indicated in PD-L1 expression >= 1%. Treatment must be initiated during 42 days from the end of chemoradiotherapy.
Then authors present the case report of patient, treated with durvalumab adjuvant immunotherapy.